Gemzar gemcitabine data

LLY (Indianapolis) received FDA advisory committee recommendation for approval of the cancer drug gemcitabine, based on data from two clinical trials (see Regulatory, page B4).

A Phase III trial comparing the drug to 5-fluorouracil (5-FU) found six-month survival of 46 percent for Gemzar and 31 percent for 5-FU. There were 63 patients in each group. ...